Dana Incorporated experienced a substantial revenue decline alongside meaningfully reduced R&D spending, signaling potential business contraction or significant operational changes.
The company's revenue dropped significantly while R&D expenses were substantially reduced, suggesting either a major business restructuring, divestiture of operations, or challenging market conditions. The combination of lower revenues with reduced investment in innovation could indicate strategic repositioning or cost-cutting measures that may impact future competitiveness.
Dana's financials show a contracting business profile with revenue declining substantially to $7.5B while operating expenses compressed across the board, including meaningfully reduced R&D spending. Despite the revenue headwinds, operating cash flow grew modestly to $512M, though this positive was offset by deteriorating balance sheet metrics including reduced stockholders' equity and higher total liabilities. The overall picture suggests significant business contraction or restructuring, with management prioritizing cash generation while scaling back operations and investment spending.
R&D spending cut 54.1% — could signal cost discipline or concerning reduction in innovation investment.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Inventory drawn down 34.4% — strong sell-through or deliberate destocking; watch for supply constraints.
Current liabilities rose 29.2% — increased short-term obligations, watch current ratio.
Revenue softened 27.1% — monitor whether this is cyclical or structural.
SG&A reduced 26.1% — improved cost efficiency or headcount reduction improving operating margins.
Receivables declined — improved collection efficiency or conservative revenue recognition.
Liabilities increased 17.1% — monitor debt-to-equity ratio and interest coverage.
Operating cash flow grew 13.8% — strong conversion of earnings to cash, healthy business fundamentals.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →